Understanding Clinical Trials | ORAL Trials
Links shared publicly online about this topic.
- 763total visits
Understanding Clinical Trials | ORAL Trials
View full resource at oraltrials.com
Tags: Arthritis, Rheumatoid Arthritis, Drug, Phase 3 Clinical Trial, Clinical Trial, Safety
Most Recently Shared on October 30, 2010 at 9:52 pm By:
Understanding Clinical Trials | ORAL Trials http://t.co/qRNDHRV via @AddThis
Treating Patients Enrolled in Clinical Trials
onclive.com — “All oncology nurses—not just nurse researchers—will need to understand the fundamentals of clinical trials as patient access to the studies continues to expand.” View full resource at onclive.com
Most Recently Shared on May 5, 2012 at 5:29 pm By:
Treating Patients Enrolled in Clinical Trials http://t.co/td7Evcaa #ONScongress
Corengi is changing the way patients discover clinical trials
imedicalapps.com — “Corengi, the AdSense of clinical trials, is using embeddable widgets on third-party website to help patients find and better understand clinical trials.” View full resource at imedicalapps.com
Most Recently Shared on April 24, 2012 at 1:29 pm By:
Corengi is changing the way patients discover clinical trials http://t.co/3norWqHX
Oral Cancer Detection Could Dramatically Increase With Saliva Test
medicalnewstoday.com — “A Michigan State University surgeon is teaming up with a Lansing-area dental benefits firm on a clinical trial to create a simple, cost-effective saliva test to detect oral cancer, a breakthrough” View full resource at medicalnewstoday.com
Most Recently Shared on April 19, 2012 at 8:05 am By:
MNT Clinical Trials Health News
Oral Cancer Detection Could Dramatically Increase With Saliva Test http://t.co/mUu4d1Vo #clinicaltrials
Drug May Lower Gluten Toxicity in Patients with Celiac Disease - Celiac.com
celiac.com — “Biopharmaceutical development company, BioLineRx, has announced results from pre-clinical trials which show that their compound, BL-7010, an orally available treatment for celiac disease, reduces the ...” View full resource at celiac.com
Most Recently Shared on April 18, 2012 at 9:19 am By:
csaceliacs Health Organization
Drug May Lower Gluten Toxicity in Patients with Celiac Disease - http://t.co/2y1rcrPk http://t.co/r31MN96a #GF #Celiac
Clinical Trial Research - Study Findings from Baylor University College of M...
newsrx.com — “Clinical Trial Research - Study Findings from Baylor University College of M...” View full resource at newsrx.com
Most Recently Shared on March 26, 2012 at 1:00 pm By:
NewsRx Medical News Health News
Study Findings from Baylor University College of Medicine Broaden Understanding of... http://t.co/4lou7zMg
Vemurafenib Effective For Some Metastatic Melanoma Patients
medicalnewstoday.com — “Results from a phase II multi-center clinical trial involving 132 patients with previously treated BRAF V600-mutant metastatic melanoma, indicate that vemurafenib (PLX4032) - an oral BRAF inhibito” View full resource at medicalnewstoday.com
Most Recently Shared on March 22, 2012 at 11:05 pm By:
Vemurafenib Effective For Some Metastatic Melanoma Patients http://t.co/H9COpZRa #skincancer #melanoma
BMC Clinical Pharmacology | Abstract | Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial
biomedcentral.com — “Consistent with its effect on gastric emptying, exenatide, an injectable treatment for type 2 diabetes, may slow the absorption rate of concomitantly administered oral drugs resulting in a decrease in maximum concentration (Cmax). This study evaluated the drug interaction potential of exenatide when administered adjunctively with oral contraceptives, given their potential concomitant use.” View full resource at biomedcentral.com
Most Recently Shared on March 20, 2012 at 9:35 pm By:
Effect of exenatide on the pharmacokinetics of a combination oral contraceptive http://t.co/NtAJ9ZIb
PaxVax announces FDA acceptance of IND for PXVX-0200 cholera vaccine
news-medical.net — “PaxVax Corporation, developer of innovative and socially responsible oral vaccines against infectious diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application for its single-dose oral cholera vaccine, clearing the way to begin clinical trials. The company intends to begin Phase 3 trials later this year.” View full resource at news-medical.net
Most Recently Shared on March 19, 2012 at 1:12 pm By:
Bird Flu News: PaxVax announces FDA acceptance of IND for PXVX-0200 cholera vaccine: PaxVax Corporation, develop... http://t.co/vN7utz5a
FDA Accepts PaxVax’s IND for Single-Dose Oral Cholera Vaccine - Yahoo! Finance
finance.yahoo.com — “From Yahoo! Finance: PaxVax Corporation, developer of innovative and socially responsible oral vaccines against infectious diseases, announced that the U.S. Food and Drug Administration has accepted its investigational new drug application for its single-dose oral cholera vaccine, clearing the way to begin clinical trials.” View full resource at finance.yahoo.com
Most Recently Shared on March 19, 2012 at 1:03 pm By:
FDA Accepts PaxVax’s IND for Single-Dose Oral Cholera Vaccine: PaxVax Corporation, developer of innovative and s... http://t.co/S88mL9v2
Oral BRAF inhibitor can extend survival to 16 months for patients with MM
news-medical.net — “An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center in Tampa, Fla., have found that the oral BRAF inhibitor vemurafenib (PLX4032) when tested in a phase II clinical trial offered a high rate of response in patients with previously treated metastatic melanoma and who had the BRAF mutation.” View full resource at news-medical.net
Most Recently Shared on March 17, 2012 at 9:26 am By:
Oral BRAF inhibitor can extend survival to 16 months for patients with MM: An international team of researchers ... http://t.co/tM2N1Vwa
Response Rate High for Some Patients with Metastatic Melanoma Treated with Vemurafenib
newswise.com — “An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center, have found that the oral BRAF inhibitor vemurafenib (PLX4032) when tested in a phase II clinical trial offered a high rate of response in patients with previously treated metastatic melanoma and who had the BRAF mutation. More than 50 percent of the patients in the trial had positive, prolonged responses and a median survival of almost 16 months.” View full resource at newswise.com
Most Recently Shared on March 16, 2012 at 4:47 pm By:
#health news: Response Rate High for Some Patients with Metastatic Melanoma Treated with Vemurafenib http://t.co/NOOLgphV
Response Rate High for Some Patients with Metastatic Melanoma Treated with Vemurafenib
newswise.com — “An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center, have found that the oral BRAF inhibitor vemurafenib (PLX4032) when tested in a phase II clinical trial offered a high rate of response in patients with previously treated metastatic melanoma and who had the BRAF mutation. More than 50 percent of the patients in the trial had positive, prolonged responses and a median survival of almost 16 months.” View full resource at newswise.com
Most Recently Shared on March 16, 2012 at 4:42 pm By:
newswise Health News and Health Communicator
Response Rate High for Some Patients with Metastatic Melanoma Treated with Vemurafenib http://t.co/J4PYO8lL
Clinical trial phases - ONA
oncologynurseadvisor.com — “This article provides detailed information about the four phases of clinical trials to help patients better understand each segment.” View full resource at oncologynurseadvisor.com
Most Recently Shared on March 14, 2012 at 3:25 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
#Cancer patients should have a solid understanding of the four phases of #clinicaltrials. This article explains them: http://t.co/JrLVuYmZ
Protein Shown to Protect against Parkinson?s by Helping Clear Out Other Damaged Protein from Brain - Parkinson's Disease Foundation (PDF)
pdf.org — “Read the latest Parkinson's news - including results from the latest Parkinson's clinical trials, recent medication approvals and other scientific discoveries.” View full resource at pdf.org
Most Recently Shared on March 12, 2012 at 6:53 pm By:
Will this protein help us understand #Parkinson's? http://t.co/KjOaAuKH @pd2007 @tpalizzi @limyoga @yumabev @robyn_mostofme @jbeck_pdf
CardioSource - Top Content
cardiosource.org — “CardioSource - Top Content” View full resource at cardiosource.org
Most Recently Shared on March 9, 2012 at 5:05 pm By:
AmerColl Cardiology Cardiology and Medical Society
Top 10 Journal Scans & Clinical Trial Summaries from February: http://t.co/PM1AG17R
Advertisement
